Radiotheranostics in oncology: current challenges and emerging opportunities

L Bodei, K Herrmann, H Schöder, AM Scott… - Nature Reviews …, 2022 - nature.com
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

[HTML][HTML] Holmium-166 radioembolization: current status and future prospective

M Stella, AJAT Braat, R van Rooij… - CardioVascular and …, 2022 - Springer
Since its first suggestion as possible option for liver radioembolization treatment, the
therapeutic isotope holmium-166 (166Ho) caught the experts' attention due to its imaging …

[HTML][HTML] Neuroendocrine liver metastases: a contemporary review of treatment strategies

JM Cloyd, A Ejaz, B Konda, MS Makary… - … surgery and nutrition, 2020 - ncbi.nlm.nih.gov
Well-differentiated neuroendocrine tumors (NETs) are globally increasing in prevalence and
the liver is the most common site of metastasis. Neuroendocrine liver metastases (NELM) …

Dose–effect relationships of 166Ho radioembolization in colorectal cancer

C van Roekel, R Bastiaannet, MLJ Smits… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Radioembolization is a treatment option for colorectal cancer (CRC) patients with
inoperable, chemorefractory hepatic metastases. Personalized treatment requires …

[HTML][HTML] Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA)

SC Ebbers, MW Barentsz… - European Journal of …, 2024 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) using [177Lu] Lu-DOTATATE has
been shown to effectively prolong progression free survival in grade 1–2 …

90Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study

BM Schaarschmidt, M Wildgruber… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe
impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y …

Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere

JL Raoul, J Edeline - The Lancet Oncology, 2020 - thelancet.com
Hepatocellular carcinoma is the fifth most common cancer and second leading cause of
cancer-related death globally. More than half of all patients are in China. For nearly 10 …

[HTML][HTML] Metastatic disease to the liver: Locoregional therapy strategies and outcomes

KE Zane, JM Cloyd, KS Mumtaz… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Secondary cancers of the liver are more than twenty times more common than primary
tumors and are incurable in most cases. While surgical resection and systemic …

[HTML][HTML] Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art

S Wu, K Fan, Q Yang, Z Chen, Y Hou, Y Zou… - Journal of …, 2023 - Springer
The process of transcatheter arterial chemoembolization is characterized by the ability to
accurately deliver chemotherapy drugs with minimal systemic side effects and has become …

[HTML][HTML] Transplantation for metastatic liver disease

AK Clift, M Hagness, K Lehmann, CB Rosen… - Journal of …, 2023 - Elsevier
The liver is a common site of metastases from many cancers, particularly those originating in
the gastrointestinal tract. Liver transplantation is an uncommonly used but promising and at …